

Bringing in the Research Dollars! (BiRD)



**Presented by:
The Emory-Children's Pediatric Research Center**

The monthly BiRD announcement highlights
pediatric research funding opportunities

If you plan to apply to any of the opportunities cited below or
for other research grants, please contact
Stacy Heilman to learn more about our
Grant Editing and Biostatistical Support Cores
that provide fully subsidized services for efforts
towards acquiring extramural research grant support.

May 2011 BIRD highlights

- Clinical trial planning grants for [Type 1 Diabetes](#) studies and for [rare thrombotic & hemostatic disorders](#) and an [early-phase clinical trial announcement for blood cell therapies](#)
- Unique opportunities to [translate medical technologies towards reducing health disparities](#), to metabolically phenotype existing cohorts in [cardiovascular and lung disease](#) and to [develop novel interventions in mental disorders](#) such as autism
- [Nutrition and physical activity research](#) to promote cardiovascular and pulmonary health
- American Heart Association National Affiliate grant opportunities supporting research [broadly related to cardiovascular function and stroke](#)
- Career development opportunities for [cancer researchers](#) and [innovative cancer research](#) as well as [biomedical basic science postdoctoral fellowships](#)
- Internal pilot opportunities for [Pediatric Nanomedicine](#) and for novel [medical device, diagnostic or imaging technologies towards improving cancer diagnosis and treatment](#)
- [Nursing research grants](#) for a variety of nurses at different stages of their research careers

Program/ Link **Translational Research for the Development of Novel Interventions for Mental Disorders (R21/R33)**
<http://grants.nih.gov/grants/guide/pa-files/PAR-11-177.html>

Purpose This funding opportunity announcement (FOA) encourages Exploratory/Developmental Phased Innovation (R21/R33) grant applications to

speed the translation of emerging findings on the neuroscience of mental disorders into novel intervention approaches that will ultimately reduce symptoms and/or restore function. This FOA provides support for up to two years (R21 phase) for preliminary, proof-of-principle studies in human participants, followed by up to 3 years of support (R33 phase) for pilot studies to assess the implementation of the intervention, and evaluate the feasibility of conducting a larger trial to assess the efficacy of the intervention. A range of non-pharmacologic treatment approaches will be accepted, including those based on neurophysiological, cognitive, affective, and/or social neuroscience models, basic behavioral science, and neurodevelopmental models. Applications submitted in response to this FOA must involve novel treatment targets, and/or novel and highly innovative approaches to engage and modify known targets.

Funds Avail The R21 phase may not exceed two years or \$325,000 in direct costs, with no more than \$225,000 in direct costs in any single year of the R21 phase. The R33 phase may not exceed three years or \$525,000 in direct costs, with no more than \$250,000 in direct costs in any single year of the R33 phase. Maximum total period of support is 5 years.

Deadline Standard NIH Due Dates*

Remarks

- Highest priority will be given to meritorious applications with the potential to address an unmet therapeutic need.
- The NIMH intends to commit approximately \$2,000,000 in FY 2012 to fund up to 8 awards in response to this FOA.
- This FOA does not support research aimed at examining the neurobiological mechanisms of existing interventions on established targets. This FOA does not support research aimed at testing novel pharmacological approaches either alone or in combination with other treatment strategies. For these types of studies, applicants should consider the R34 FOAs for pilot studies noted above or the Research Project Grant (Parent R01)

Program/ Early-Phase Clinical Trials for Blood Cell Therapies (R01)

Link <http://grants.nih.gov/grants/guide/pa-files/PAR-11-204.html>

Purpose This FOA issued by the National Heart, Lung, and Blood Institute, National Institutes of Health, encourages Research Project Grant (R01) applications from institutions and organizations for the purpose of accelerating translation of new preclinical stem cell and cell therapy research advances into new cell therapies to treat blood diseases and/or to improve the outcome of hematopoietic stem cell transplantations. These first-in-human, phase I, phase II, or phase I/II clinical trials will investigate new cell therapy methods and could include testing new cell types, differentiation protocols, or other strategies.

Funds Avail Application budgets are not limited, but need to reflect actual needs of the proposed project. Maximum project period is 5 years.

Deadline October 5, 2011 and 2012
(AIDS Application Due Dates are Jan 7, 2012 and 2013)

- Remarks**
- Basic researchers that may lack clinical experience are strongly encouraged to ask for assistance from three NHLBI resource programs: the Production Assistance for Cellular Therapies or PACT, the Gene Therapy Resource Program or GTRP, and/or the Science Moving towards Research Translation and Therapy or SMARTT. In addition to furnishing important key clinical-grade resources such as cells, vectors, or biologics, the coordinating centers of these programs can provide cell regulatory support, as well as data collection and statistical support related to the use of these resources in early phase clinical trials.
 - This initiative seeks applications that consider new cell therapies for blood diseases and cell therapies adjunct to hematopoietic stem cell transplantation. Applications using minimally manipulated cell therapy products (see FDA Guidance documents on minimally manipulated products at: <http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/default.htm>) should consider [PA-10-067](#) (Parent R01) or other FOAs as appropriate.
 - Investigators planning trials and developing clinical protocols for cell therapy applications to this FOA are encouraged to consult the coordinating centers at these resource programs as well as the NHLBI program staff listed in the RFA

This opportunity is being pursued by a collaborative group within the Children's Transplant Immunology & Immune Therapeutics Center

Program/ Link **Clinical Trial Planning Grants in Type 1 Diabetes (R34)**
<http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-11-010.html>

Purpose This FOA provides for planning grants for clinical trials related to type 1 diabetes. It is expected that these planning grants will lead to clinical trials to test interventions designed to improve glycemic control and/or to treat or reduce diabetes complications. The intent of this initiative is to improve the management and treatment of individuals with type 1 diabetes in the United States. If successful, the results of the future clinical trials should be of practical importance to clinical management and applicable immediately. The purpose of this FOA is not to validate new technologies or test new therapeutics.

Funds Avail Applications may request up to \$100,000 in direct costs and the project period is for 1 year.

Deadline March 15, 2012

- Remarks**
- The R34 Planning Grant is intended to support all administrative study group activities that are required in order to begin recruitment of subjects. These activities include, but are not limited to: establishing the research team, developing tools for data management and oversight of the research, defining recruitment strategies, finalizing the protocol, writing the Manual of Operations, establishing a data and safety monitoring plan, and initiating the IRB approval process.
 - The R34 Planning Grant application should include a fully developed trial protocol and trial budget for future consideration. The R34 Planning Grant is not

for the collection of preliminary data or the conduct of pilot studies to support the rationale for a clinical trial.

- NIH anticipates funding of up to 6 R34 planning grants and up to three full scale trials from the funded R34 planning grants

Program/ Link **Nutrition and Physical Activity Research to Promote Cardiovascular and Pulmonary Health (R01)**

<http://grants.nih.gov/grants/guide/pa-files/PA-09-243.html>

Purpose This FOA encourages Research Project Grant (R01) applications that propose research on the roles of nutrition and physical activity in the development, prevention, and management of cardiovascular diseases (CVD) or pulmonary diseases. In particular, the FOA aims to (1) improve knowledge of the contribution of diet and physical activity to these conditions and how sleep influences these relationships, (2) increase the evidence base for refining public health recommendations and clinical guidelines regarding these lifestyle behaviors, and (3) develop and test strategies to improve the adoption of these recommendations.

Funds Avail Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. Project periods may not exceed 5 years.

Deadline Standard NIH Deadlines*

- Remarks**
- Runs in parallel with a FOA of identical scientific scope, <http://grants.nih.gov/grants/guide/pa-files/PA-09-244.html> that encourages applications under the R21 grant mechanism.
 - Participating organizations include NHLBI, NCCAM and NINR

Program/ Link **Clinical Trials Planning Studies for Rare Thrombotic and Hemostatic Disorders (U34)**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-12-023.html>

Purpose Inviting applications to obtain critical and necessary support in the planning and development of feasible and well designed multicenter clinical trials focused on rare hemostatic and thrombotic disorders, or on more common hemostatic and thrombotic disorders that occur rarely in special patient populations (for example: neonates, children, pregnant women).

Funds Avail Direct costs are limited to \$450,000 over a three-year period, with no more than \$225,000 in direct costs allowed in any single year.

Deadline October 13, 2011, October 15, 2012, October 17, 2013, by 5:00 PM local time of applicant organization.

- Remarks**
- The Clinical Trials Development Resource for Hematologic Disorders (U24) (RFA-HL-12-016) will provide guidance to investigators on trial design, biostatistics, clinical trial management, and regulatory requirements during the funding period.

- The Clinical Trial Planning Grant Program is not designed for the collection of preliminary data or the conduct of pilot studies to support the rationale for a clinical trial. Applicants should consider : NHLBI Clinical Trial Pilot Studies (R34) as a potential funding mechanism to support pilot or feasibility studies - <http://grants.nih.gov/grants/guide/pa-files/PAR-10-005.html>

Program/ Anchoring Metabolomic Changes to Phenotype (P20)*

Link <http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-12-009.html>

Purpose Issued by the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health, encouraging applications from institutions or organizations that propose metabolomic phenotyping of existing cohorts to gain mechanistic understanding of the molecular determinants contributing to cardiovascular and lung disease phenotypes to help in predicting disease susceptibility, diagnosis, risk stratification, assessing response to therapy and assessing prognosis. Applicants should propose facilitating the capture of molecular information that is most proximal to a cardiovascular or lung disease phenotype of interest and use that to gain mechanistic understanding of the pathways and mediators involved in the expression of the phenotype. The FOA proposes a multidisciplinary and integrated program with two interacting components, a metabolomic component and a mechanistic component, each informing the other in an iterative manner. The specific objectives of this program are (1) the identification of distinct metabolites and metabolomic profiles for specific cardiovascular and lung phenotypes, (2) identification of candidate pathways and genes responsible for the generation of the distinct metabolites and metabolomic profiles of specific phenotypes, and (3) identification of (a) novel and potential targets for intervention and (b) novel biomarkers.

Funds Avail Each budget year may not exceed the following direct cost thresholds: Year One and Year Five \$450,000. Years Two, Three and Four \$750,000. Additionally, applicants may request up to \$130,000 in direct costs for an Administrative Core, for each of the five years

Deadline June 17, 2011 (LOI due May 17, 2011)

Remarks

- *P20 grants are to support planning for new programs, expansion or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers.
- A multicomponent application is to be submitted, consisting of a metabolomic center and an administrative core.
- Applicants must propose a multidisciplinary team structure ensuring effective coordination and integration between the metabolomic and mechanistic components of the program. The team should include metabolomics experts, investigators familiar with all aspects of the parent studies from which samples are being used, experts in basic science and pathway analysis and experts in

biostatistics and bioinformatics. Only projects that propose studies based on existing resources will be considered responsive.

Program/ Link **Development and Translation of Medical Technologies to Reduce Health Disparities (R43/R44)**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-EB-11-001.html>

Purpose This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop and translate medical technologies aimed at reducing disparities in healthcare access and health outcomes. Appropriate medical technologies should be effective, affordable, culturally acceptable, and deliverable to those who need them. Responsive grant applications must involve a formal collaboration with a healthcare provider or other healthcare organization serving a health disparity population during Phase I and Phase II. This announcement supports applications to develop medical devices, imaging systems, and other technologies that adequately address the healthcare needs of health disparity populations. It is expected that responsive grant applications will result in advances in medical technologies that will be invaluable in reducing health disparities within and across the priority areas of cardiovascular disease, stroke, cancer, diabetes, HIV/AIDS, infant mortality, mental health, and obesity, as well as lung, liver, and kidney diseases, psoriasis, scleroderma, and other diseases, illnesses, and conditions of public health importance.

Funds Avail Budgets up to \$200,000 total costs per year for Phase I and up to \$400,000 total costs per year for Phase II may be requested.

Durations up to 2 years for Phase I and up to 3 years for Phase II may be requested.

Deadline Sept 22, 2011
(AIDS deadlines are Sept 7, 2011 and Jan 7, 2012)

Remarks ➤ Participating organizations include National Institute of Biomedical Imaging and Bioengineering, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute on Minority Health and Health Disparities & National Center for Research Resources

An application in response to this opportunity must involve a small business, but could be a good collaborative with Children's, GA Tech and/or Morehouse. Contact stacy.heilman@emory.edu if you would like to explore possibilities.

Program/ Link **American Heart Association National Affiliate Grant Opportunities**
http://my.americanheart.org/professional/Research/FundingOpportunities/Funding-Opportunities_UCM_316909_SubHomePage.jsp

Purpose Offering funding opportunities for various stages and scopes of research including:

1. **Scientist Development Grant** - Supports highly promising beginning scientists in their progress toward independence by encouraging and adequately funding research projects that can bridge the gap between completion of research training and readiness for successful competition as an independent investigator. *Supports research broadly related to cardiovascular function and disease and stroke, or to related clinical, basic science, bioengineering or biotechnology, and public health problems, including multidisciplinary efforts.*
2. **Clinical Research Program** - Encourages early career investigators who have appropriate and supportive mentoring relationships to engage in high quality introductory and pilot clinical studies that will guide future strategies for reducing cardiovascular disease and stroke while fostering new research in clinical and translational science, and encouraging community- and population-based activities. *This grant does not fund basic science or support senior researchers, but encourages mentoring of early career investigators.*
3. **Established Investigator Award** - To support mid-term investigators with unusual promise and an established record of accomplishments; candidates have a demonstrated commitment to cardiovascular or cerebrovascular science as indicated by prior publication history and scientific accomplishments. A candidate's career is expected to be in a rapid growth phase. *Supports research broadly related to cardiovascular function and disease and stroke, or to related clinical, basic science, bioengineering or biotechnology, and public health problems, including multidisciplinary efforts.*
4. **Innovative Research Grant** - To support highly innovative, high-risk, high-reward research that could ultimately lead to critical discoveries or major advancements that will accelerate the field of cardiovascular and stroke research. Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities. The Innovative Research Grant (IRG) promotes new ideas; therefore, proposals need not include preliminary data. However, a solid rationale for the work must be provided. Proposed work should not be the next logical step of previous work, but should have a high probability of revealing new avenues of investigation, if successful. This program aims to provide pilot or seed funding that should lead to successful competition for additional funding beyond the pilot period. The principal investigator (PI) is responsible for clearly and explicitly articulating the project's innovation and the potential impact on cardiovascular and stroke research. *Supports research broadly related to cardiovascular function and disease and stroke, or to related clinical, basic science, bioengineering or biotechnology, and public health problems, including multidisciplinary efforts.*

Funds Avail

1. Scientist Development Grant - \$77,000 annually for 4 years
2. Clinical Research Program - \$55,000 annually for 2 years

3. Established Investigator Award - \$80,000 annually for 5 years
4. Innovative Research Grant - \$75,000 annually for 2 years

Deadline July 8, 2011 (for all opportunities listed)

Remarks ➤ Go to individual program links to review details of each opportunity's scope. AHA has many restrictions so review criteria carefully. Contact stacy.heilman@emory.edu for help navigating through the program descriptions.

Program/ Link **The Damon Runyon Cancer Research Foundation Innovation Award**
http://www.damonrunyon.org/for_scientists/more/innovation_award_application_guidelines

Purpose The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer.

The Innovation award is specifically designed to provide funding for extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field. Awards are made to institutions for support of the Damon Runyon-Rachleff Innovation Investigators.

Funds Avail Each award will provide a total of \$450,000 in direct costs over 3 years. The award cannot be used for indirect costs or institutional overhead. Awards will be paid in increments of \$150,000 per year for 3 years.

Deadline Pre-Proposals due June 1, 2011

Remarks ➤ Applicants are expected to commit a minimum of 80% of their time to conducting research.

➤ Applicants (including non-U.S. citizens) must be conducting independent research at a U.S. research institution.

➤ Basic and translational/clinical projects will be considered. Applications will be accepted from all scientific disciplines provided that the proposed research meets the selection criteria.

➤ Applicants with a background in multiple disciplines are especially encouraged to apply.

➤ Applicants must belong to one of the following categories:

- Tenure-track Assistant Professors within the first three years of obtaining their initial Assistant Professor position. (Cut-off date: June 1, 2008.)
- Clinical Instructors and Senior Clinical Fellows (in their final year of their sub-specialty training) holding an MD who are pursuing a period of independent research before taking a tenure-track faculty position. Such

individuals must have an exceptional record of research accomplishment, dedicated laboratory space and the support of their institution.

- Distinguished Fellows with an exceptional record of research accomplishment identified by their institution to pursue an independent research program and who have dedicated laboratory space. These candidates are markedly distinct from traditional postdoctoral fellows.

Program/ Children's Cancer Research Fund

Link <http://www.childrenscancer.org/>

Purpose The Los Angeles-based Children's Cancer Research Fund was established in 1987 to provide support on a national level for clinical research in the field of childhood cancer. The fund's annual research grant program is focused on the diagnosis, treatment, and side effects of therapy of childhood cancer. The purpose of the grant program is to support investigators at the postdoctoral level (M.D. or Ph.D.) working on innovative pilot clinical studies that have the potential to develop new insights into clinical aspects of childhood cancer. Applications by senior fellows and junior faculty investigators are particularly encouraged. Applications from well-funded senior investigators will not be considered.

Funds Avail \$40,000

Deadline June, 17, 2011

Remarks ➤ Contact stacy.heilman@emory.edu for a copy of the application guidelines

Program/ Helen Hay Whitney Foundation, Postdoctoral Research Fellowship

Link <http://www.hhwf.org/HTMLSrc/ResearchFellowships.html>

Purpose The Helen Hay Whitney Foundation supports early postdoctoral research training in all basic biomedical sciences. To attain its ultimate goal of increasing the number of imaginative, well-trained and dedicated medical scientists, the foundation grants financial support of sufficient duration to help further the careers of young men and women engaged in biological or medical research.

Funds Avail Stipend (\$48K in year 1, \$49K in year 2 and \$50K in year 3) plus \$2500 research allowance and some travel expenses allowed annually for a 3 year period

Deadline July 14, 2011 by 5pm

Remarks

- Candidates who hold, or are in the final stages of obtaining a Ph.D., M.D., or equivalent degree and are seeking beginning postdoctoral training in basic biomedical research are eligible to apply for a fellowship.
- Candidates should have no more than one year of postdoctoral research experience at the time of the deadline for submitting the application (July 14),
- Candidates must not have received their PhD degree more than *two years*

before the deadline, or an M.D. degree more than *three years* before the deadline.

- Less than 5% of those who apply will receive awards

Program/ Link **The Children's Center for Pediatric Nanomedicine (CPN) Pilot Request for Applications**

<http://www.pedsresearch.org/centers/sub-pages/center-for-pediatric-nanomedicine-call-for-proposal>

Purpose The intent of the seed grant program is to build strong collaborations and interdisciplinary projects leading to new *extramural funding* related to pediatric nanomedicine. It is expected that the pilot projects supported by the seed grants will foster the formation of research teams consisting of bioengineers, scientists and clinicians, and integrate pediatric nanomedicine research activities at Children's, Georgia Tech and Emory University. Areas of research focus will include **cancer, cardiovascular disease, infectious disease**, and genetic diseases such as **sickle cell disease** and **cystic fibrosis**.

Funds Avail \$60,000 direct costs per pilot project, available for one year (08/01/11-07/31/12).

Deadline July 1, 2011

- Remarks**
- All faculty (including Research Faculty) members from Children's, Georgia Tech, Emory University and Morehouse School of Medicine are eligible to apply for seed grant funds.
 - Multiple Principal Investigators are strongly encouraged, and *at least one of the Co-PIs should be an investigator in Pediatrics at Emory or Morehouse, or on the professional staff of Children's Healthcare of Atlanta.*
 - Renewal of a project for a second year will be considered in 2012 on a competitive basis.
 - It is expected that 8 pilot projects will be awarded for 2011.

Program/ Link **Joint Winship Cancer Institute/ACTSI Translational Research Grant Program**

http://www.actsi.org/news/2011/documents/wci_actshiv2.pdf

Purpose Resources are being pooled between Winship and the ACTSI to provide support for novel medical device, diagnostic or imaging technologies that substantially enhance the diagnosis or treatment of cancer. Outcomes required to achieve this goal include follow-on funding, inventions, patent applications, licenses and commercial products.

Funds Avail Grants are expected to range from \$50,000 – \$75,000 for a one-year period

Deadline June 30, 2011 at 5pm

- Remarks**
- This is a multiple-PI grant. At least one PI must be a member of the Winship Cancer Institute. The other PI must be permanent faculty in the professorial ranks (assistant, associate, or full) from Emory University, MSM or Georgia Tech.
 - Collaboration of PIs from different disciplines and from different institutions is preferred but not required.
 - The 5 page body of the proposal must contain the following information:
 - A description of the unmet clinical need and business, market, or clinical application opportunity
 - Overall project goals, approximate timing to achieve them, and expected outcomes
 - Specific first-year milestones (per quarter) and a plan for achieving them
 - Plan for extramural (e.g., NIH) funding after this award expires, consistent with overall project goals and timing
 - List of current funding and pending proposals for each co-investigator (including dollar amount)
 - If needed, approval status for animal and human subjects

Program/Link Alex's Lemonade Stand Nursing Grants

<http://www.alexlemonade.org/grants/nursing>

Purpose Alex's Lemonade Stand Foundation's Nursing Grant Program is designed to improve the quality of life for young cancer patients and their families. Grant programs include 1) Mentored Nurse Researcher Grants designed to support the efforts of beginning nurse researchers to accomplish small research projects with both mentor and institutional support, 2) Intermediate Nurse Researcher Grants designed to finally support efforts of more experienced nurse researchers to accomplish research projects with the support and commitment of the institution where they practice and 3) Independent Nurse Researcher grants that are expected to be from experienced investigators that demonstrate a commitment to pediatric cancer nursing.

Funds Avail Mentored Nurse Researcher - \$20,000
Intermediate Nurse Researcher - \$40,000
Independent Nurse Researcher - \$100,000
Funding is over 2 years

Deadline August 1, 2011 by 11:59 PM ET

*NIH STANDARD DUE DATES CITED ABOVE

Mechanism(s)	Cycle I Due Date	Cycle II Due Date	Cycle III Due Date
P Series ALL – new, renewal, resubmission, revision	25-Jan	25-May	25-Sept
R01 NEW <i>renewal, resubmission, revision</i>	5-Feb <i>5-Mar</i>	5-Jun <i>5-Jul</i>	5-Oct <i>5-Nov</i>
R03, R21, R34 NEW <i>renewal, resubmission, revision</i>	16-Feb <i>16-Mar</i>	16-Jun <i>16-Jul</i>	16-Oct <i>16-Nov</i>
K series NEW <i>renewal, resubmission, revision</i>	12-Feb <i>12-Mar</i>	12-Jun <i>12-Jul</i>	12-Oct <i>12-Nov</i>
All AIDS and AIDS-Related Applications (for mechanisms cited above) <i>All - new, renewal, resubmission, revision</i>	7-May	7-Sept	7-Jan

For the full schedule of NIH standard due dates, see
<http://grants1.nih.gov/grants/funding/submissionschedule.htm>



ABOUT THE BIRD:

This compilation of general interest funding opportunities and announcements with possible collaborative potential is distributed to our pediatric research community monthly. It is compiled by the Emory-Children's Pediatric Research Center to disseminate funding announcements of potential interest in a consolidated manner. More specific announcements are distributed in a more targeted fashion.

If you are not receiving this directly from Stacy Heilman and wish to be added to our Pediatric Research listserv, please e-mail stacy.heilman@emory.edu to make the request. Please also contact Stacy if you are interested in applying for any research funding opportunities and/or if you are interested in building collaborative efforts and programs towards applying for future funding.

This e-mail message (including any attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this message (including any attachments) is strictly prohibited.

If you have received this message in error, please contact the sender by reply e-mail message and destroy all copies of the original message (including attachments).